Agoracom Blog

Supreme Appoints John Fowler President & Director

Posted by AGORACOM-JC at 1:47 PM on Friday, December 19th, 2014

VANCOUVER, BRITISH COLUMBIA–(Dec. 19, 2014) – Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (OTC PINK:SPRWF)(CSE:SL) is pleased to report that at its annual meeting today John Fowler was elected to the board of directors and appointed as the President of the Company. The Company has also added Dr. Youbin Zheng to its advisory board.

Mr. John Fowler, previously Director of Operations, was elected to the board of directors, and will be assuming the position of President of Supreme. Mr. Fowler began working in the medical marijuana sector over ten years ago. He pursued a career in law to assist medical marijuana patients with legal issues ancilliary to medical marijuana use. Most recently, Mr. Fowler practiced law at a prominent Toronto law firm. Mr. Fowler is committed to providing Canadians access to high-quality, low-cost medical marijuana and working with the medical community to improve physician education and support for medical marijuana.

Dr. Youbin Zheng, PhD, MPhil, MAg, Bag, has been appointed as the newest member of the Company’s advisory board. Mr. Zheng is currently an Associate Professor and Environmental Horticulture Chair, at the University of Guelph. He has many years of experience in horticulture research, especially in vegetable and ornamental plant production in controlled environments (e.g. greenhouses) in Canada, England, Japan and China. Recent research projects include greenroofs, urban agriculture, organic vegetable production in greenhouses, CO2 enrichment and its effects on photosynthesis, respiration, transpiration, nutrient uptake and crop production, irrigation and water treatment for sustainable horticulture, and the development of sustainable plant production systems. Mr. Zheng is a highly distinguished expert in the field of horticulture and will be a key advisor to the Company and its grow operations moving forward.

The Company has agreed to settle certain payment obligations pursuant to a consulting agreement by the issuance of 390,000 common shares of the Company on January 2, 2015.


This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the up grading of the facility, the timing on completion of the MMPR License conditions and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on and such factors as the Company failing to finish the upgrading of the facility and put the same into production in accordance within the terms of the MMPR license. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
430 – 580 Hornby Street, Vancouver BC, V6C 3B6
[email protected]

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway:

Tags: , , , , ,

Comments are closed.